Loading patent…
AssigneeThe Green Cross Corporation
InventorsSatoshi Funakoshi, Takao Omura, Takeshi Ohshiro
Estimating the term…
An aqueous solution of haptoglobin is obtained by subjecting an aqueous solution of .alpha. and .beta.-globulin fractions of human blood plasma to further fractionation by use of ammonium sulfate, collecting fractions precipitated at a concentration between 30% and 40% saturation of ammonium sulfate, contacting a reconstituted aqueous solution of the collected fractions with an anion exchanger to adsorb haptoglobin on said anion exchanger, selectively eluting the haptoglobin from the anion exchanger, and then concentrating the resulting aqueous eluate solution. The aqueous solution of haptoglobin is subjected to heat treatment in the presence of a selected stabilizing agent for inactivating hepatitis B virus at an optional step of the process. The thus obtained aqueous solution of haptoglobin has less than 10% hypotensive activity, highly stable during storage, and free from the risk of hepatitis B virus infection. This haptoglobin preparation is used for prevention and treatment of renal disorders caused by hemolysis.
An aqueous solution of human serum haptoglobin suitable for the therapy of renal disorders derived from massive hemolysis which has less than 10% in hypotensive activity, is highly stable during storage and which has been subjected to heat treatment in the presence of at least one stabilizing agent selected from the group consisting of neutral amino acids, monosaccharides, disaccharides and soluble sugar alcohols, for inactivating hepatitis B virus (HB-Ag).
Dependencies are inferred from the claim text.